Become a Creator today!Start creating today - Share your story with the world!
Start for free
00:00:00
00:00:01
Angiotensin II for Vasodilatory Shock
9 Plays6 years ago
In our first episode of the Critical Matters podcast, we discussed the potential role of Angiotensin II in the treatment of distributive shock based on the results of the ATHOS 3 clinical trial. Now Angiotensin II is FDA approved and commercially available as a product named GIAPREZA™. In this episode we will discuss this topic further.
Our guest is Dr. Lakhmir S. Chawla, Chief Medical Officer of La Jolla Pharmaceutical in San Diego, California. Previously, Dr. Chawla was a Professor of Medicine at the George Washington University. During his tenure at George Washington, Dr. Chawla was the designer and lead investigator of the ATHOS (Angiotensin II for the Treatment of High Output Shock) trial which results led to the ATHOS 3 trial, (The Phase 3 clinical trial of angiotensin II, for the treatment of catecholamine-resistant hypotension).
Additional Resources:
ATHOS-3 Clinical Trial. Randomized controlled trial evaluating the efficacy of Angiotensin II in raising blood pressure in vasodilatory shock. http://www.nejm.org/doi/full/10.1056/NEJMoa1704154
Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II. https://www.ncbi.nlm.nih.gov/pubmed/?term=Outcomes+in+Patients+with+Vasodilatory+Shock+and+Renal+Replacement+Therapy+Treated+with+Intravenous+Angiotensin+II
Prescribing information for Angiotensin II (GIAPREZA ™ ). http://giapreza.com/giapreza-prescribing-information.pdf
Books Mentioned in This Episode:
Atlas Shrugged: https://www.amazon.com/Atlas-Shrugged-Ayn-Rand/dp/0451191145/ref=sr_1_1?ie=UTF8&qid=1522104389&sr=8-1&keywords=atlas+shrugged+book
Recommended
Transcript
Introduction to Critical Matters Podcast
00:00:09
Speaker
Welcome to Critical Matters, a sound critical care podcast covering a broad range of topics related to the practice of intensive care medicine.
00:00:17
Speaker
And now, your host, Dr. Sergio Zanotti.
00:00:22
Speaker
Welcome to another episode of Critical
Angiotensin-2 in Shock Treatment
00:00:24
Speaker
Matters.
00:00:24
Speaker
In our first episode of the podcast, we discussed the potential role of Agitensin-2 in the treatment of distributive shock based on the results of the ATHOS III clinical trial.
00:00:34
Speaker
Now angiotensin 2 is FDA approved and commercially available as a product named Gypressa.
00:00:39
Speaker
In this episode, we will discuss this topic further.
Introducing Dr. Lakmir Chawla
00:00:43
Speaker
It's a great pleasure to have as our guest, Dr. Lakmir Chawla.
00:00:47
Speaker
Dr. Lakmir Chawla is Chief Medical Officer at La Jolla Pharmaceutical Company in San Diego.
00:00:53
Speaker
Previously, Dr. Chawla was a Professor of Medicine at the George Washington University, where he had dual appointments in the Department of Anesthesiology and Critical Care Medicine and the Department of Medicine, the Division of Renal Disease and Hypertension.
00:01:05
Speaker
Dr. Chawla was also the Chief of the Division of Intensive Care Medicine at the Washington, D.C.
00:01:09
Speaker
Veterans Affairs Medical Center.
Dr. Chawla's Role in ATHOS Studies
00:01:11
Speaker
During his tenure at George Washington, Dr. Chawla was a designer and lead investigator of the ATHOS study, which was the angiotensin II for the treatment of high output shock trial, which results led to the phase III trial, ATHOS III, and the eventual approval of this new therapy.
00:01:28
Speaker
Dr. Chawla is an internationally renowned expert and investigator in the field of acute kidney injury, shock, continuous renal replacement therapy, dialysis, and abdomen dialysis.
00:01:40
Speaker
Dr. Chawla is also the author of over 100 peer-reviewed publications and was previously an associate editor of the Clinical Journal of the American Society of Nephrology.
00:01:49
Speaker
Mink, it's a real pleasure to have you on Critical Matters.
00:01:52
Speaker
Welcome.
00:01:54
Speaker
Thank you very much, Sergei.
00:01:55
Speaker
Delighted to be here.
Disclosure and Transparency
00:01:56
Speaker
So I think that a great point to start would be with a little bit of history of angiotensin II.
00:02:01
Speaker
Some of our listeners might be aware that this is not a brand new drug.
00:02:04
Speaker
It was around before, and somehow you found it, resurrected it, and brought it back into play in critical care.
00:02:11
Speaker
Can you tell us about that?
00:02:13
Speaker
Sure, absolutely.
00:02:14
Speaker
And before we get rolling, let me just disclose a little bit further.
00:02:18
Speaker
I know that you had mentioned this at the beginning, but just everyone's absolutely clear that
00:02:23
Speaker
Currently, I am on sabbatical working as the chief medical officer of La Jolla Pharmaceutical, and La Jolla Pharmaceutical was the sponsor of the 8-Dose-3 trial and the manufacturer of angiotensin-2, trade name Geopreza.
00:02:36
Speaker
So everyone should recognize that despite 20 years in academics and being a professor, I currently work at this company, and people should frame all of their opinions based on the fact that this conflict
00:02:49
Speaker
exists, I will embark to try and keep this in a very scientific conversation.
00:02:55
Speaker
But I do want to let the listeners know.
00:02:57
Speaker
Thank you.
00:02:57
Speaker
Thanks for that.
History of Angiotensin-2
00:02:59
Speaker
So basically, the history of angiotensin II, we've all learned in medical school, and it's really quite remarkable.
00:03:06
Speaker
It was first really discovered from the goldblatt kidneys, which is when you took a clamp on the renal artery and induced renal artery stenosis.
00:03:14
Speaker
And obviously, those animals became hypertensive.
00:03:17
Speaker
And over time,
00:03:19
Speaker
they discovered renin and of course angiotensin-1 being converted to angiotensin-2.
00:03:24
Speaker
And that discovery occurred in the late 1930s, which is kind of impressive what people were able to do almost over 100 years ago.
00:03:32
Speaker
And then peptide chemistry got sufficiently good enough that in the late 1950s in Basel, Switzerland at Sibahigi and also at the Cleveland Clinic,
00:03:44
Speaker
they were able to synthesize the first angiotensin II in the late 50s, and that was bovine angiotensin.
00:03:51
Speaker
So it wasn't human.
00:03:53
Speaker
The peptides required to make the human peptide were not sufficiently robust enough for them to do it.
00:03:59
Speaker
So they made a form of bovine angiotensin II, which was quite potent and entered clinical practice.
00:04:05
Speaker
in the 1960s.
00:04:07
Speaker
In fact, the first large trial of angiotensin II was actually published in an obscure journal called JAMA, which as a joke, of course, is not obscure and was not obscure in the 1960s.
00:04:20
Speaker
And there was a paper demonstrating that angiotensin II was quite effective in shock.
00:04:25
Speaker
And if you look from the 1960s, you'll find many, many articles of angiotensin II being used in shock and being quite effective.
00:04:35
Speaker
And it was primarily utilized in those days for catecholamine rescue.
Market Withdrawal and Rediscovery
00:04:40
Speaker
It ended up not being favorable for first-line therapy.
00:04:44
Speaker
And it was used primarily in clinical practice for patients with post-op cardiac vasoplegia.
00:04:53
Speaker
When you travel around, which I had the opportunity to do in developing the Atheros III trial,
00:04:59
Speaker
The only people who'd ever used bovine angiotensin II who were still alive and practicing, or at least the ones I had met, all of them were people who worked in the cardiac ICU.
00:05:09
Speaker
And I met one person in the US and around 10 in Europe
00:05:14
Speaker
And that's where they said it worked well.
00:05:16
Speaker
And in fact, one person got quite upset with me and said, how come you took it away?
00:05:20
Speaker
Which was kind of amusing since it was removed from the market well before my interest began into it.
00:05:27
Speaker
And sometime in the late 90s, Ciba, which was the company that made bovine angiotensin II, was bought by Novartis.
00:05:39
Speaker
And as part of this sort of very interesting story going back in time, I had the opportunity to meet someone who worked at SIBA when the Bartas bought them, who worked in the Angiotensin II scientific arm.
00:05:52
Speaker
And I asked her, I said, you know,
00:05:55
Speaker
What happened was the drug was drawn for safety issues, which I think is an obvious important issue.
00:06:01
Speaker
And they said, no, we had detected no safety issues whatsoever.
00:06:04
Speaker
The drug was actually doing reasonably well as a product for the company.
00:06:09
Speaker
But they made a decision that it wasn't making enough money, which is, I know, an extraordinarily weird thing to hear.
00:06:15
Speaker
But this is what's common in the business world.
Research and Effects on Renal Blood Flow
00:06:18
Speaker
And Novartis was primarily interested in SIVA's outpatient drugs and did not have a large inpatient commercial group.
00:06:26
Speaker
And so they killed the drug and they withdrew the NDA, meaning that they withdrew the drug actively from the market.
00:06:32
Speaker
And this was something which, you know, is not published anywhere.
00:06:37
Speaker
This is sort of talking to people and understanding what happened.
00:06:40
Speaker
And this all occurred and angiotensin II, which was available at the bedside, went away.
00:06:48
Speaker
And then my interest in angiotensin II began with Ronaldo Bolomo's paper where he took sheep and as a nephrologist and an intensivist, my interest was in acute kidney injury.
00:07:01
Speaker
And he did a very elegant study where he took sheep and they implanted into the sheep multiple monitors surgically and then they allow the sheep to heal up and then they give the sheep an E. coli intravenous infusion.
00:07:15
Speaker
And
00:07:16
Speaker
In this infusion, Rinaldo's group, Clive May and others down in Melbourne, Australia, demonstrated quite beautifully that in shock, the renal blood flow goes up, not down.
00:07:31
Speaker
And in fact, as an aside, which doesn't necessarily have anything to do with angiotensin II per se, but we had largely been told that
00:07:41
Speaker
real blood flow in shock goes down and that's why you get acute tuberculosis.
00:07:45
Speaker
And in fact, when you look at animal studies and animal models and you look at the human data, quite the opposite is true.
00:07:52
Speaker
Real blood flow goes up in vasodilatory shock when it's resuscitated.
00:07:57
Speaker
And what you find though, is that the creatinine clearance still goes down, the FINA goes down, and this is largely due to microcirculatory defect in efferent vasodilation.
00:08:09
Speaker
So in essence,
00:08:11
Speaker
being in shock is like getting an ACE inhibitor for the kidney.
00:08:15
Speaker
And what Rinaldo beautifully showed in a follow-up trial is when you give angiotensin to these septic sheep, you restore GFR, urine output goes up, creatinine clearance goes up, and everything gets better.
Pilot Trial on Human Angiotensin-2
00:08:28
Speaker
And so I looked at this animal study and I thought, well, this is very interesting.
00:08:32
Speaker
And I started to read about it.
00:08:34
Speaker
And as you read backwards and you start taking papers and having them get
00:08:41
Speaker
flipped over from microfiche, which was sort of an amusing process.
00:08:44
Speaker
Some of your listeners don't know what microfiche is, but there are all these old archive pieces of data.
00:08:53
Speaker
And what we find from those is that angiotensin II was widely used and a rescue drug for shock.
00:09:00
Speaker
So I wanted to bring angiotensin II into a study to use it for acute kidney injury, but the problem was that we didn't even know what the appropriate dose would be.
00:09:11
Speaker
So we had one big question is what's the correct dose?
00:09:14
Speaker
And the second issue is that if you want to give it for acute kidney injury, we at the time that I did my pilot trial did not have very effective biomarkers to give you an early identification point for which you would actually start the infusion.
00:09:29
Speaker
And in fact, when you're bringing a new drug out, usually the safest way to do it is to do it in very sick patients.
00:09:36
Speaker
And because there were very compelling data in the bovine angiotensin that it could rescue patients with catecholamine-resistant hypotension, that's the study we embarked out to do.
00:09:47
Speaker
And that's how the ATHOS pilot trial was initiated.
00:09:51
Speaker
So by now, the peptide chemistry had gotten good enough that they were able to make human angiotensin, too.
00:10:00
Speaker
So we opened up an IND, we went through our B process, we acquired human angiotensin II, and we did a 20-person pilot trial in patients who were on high-dose vasopressors.
00:10:13
Speaker
And effectively, that means they were at least on 20 mikes per minute of norepinephrine.
00:10:17
Speaker
For those of you who dosed some mikes per kilo per minute, it was all around 0.2.
00:10:22
Speaker
And in our group at George Walsh at the time, we used vasopressin for patients who were at this dose.
Pilot Trial Results and Patient Sensitivity
00:10:30
Speaker
So nearly all the patients, I believe it was 19 out of the 20, were on vasopressin at the time.
00:10:35
Speaker
And what we found in that pilot trial was that angiotensin II performed exactly like it did historically, and it was able to raise blood pressure.
00:10:47
Speaker
And I think a lot of people have sort of made the point that, well, you know, Mink, I mean, the number one selling antihypertensive in the world blocks the angiotensin II.
00:10:56
Speaker
It makes sense that angiotensin II would raise blood pressure.
00:10:59
Speaker
And I think that's right.
00:11:00
Speaker
I largely agree with that, of course.
00:11:03
Speaker
But it was not entirely clear to me that when you have profound vasodilatory shock and your nitric oxide is massively upregulated,
00:11:12
Speaker
whether you could actually get any lift.
00:11:15
Speaker
And what we found is 100% of the patients who got drug enjoyed a blood pressure increase such that we were able to rapidly down titrate the norepinephrine.
00:11:25
Speaker
But the really striking finding in a rather small trial was that two out of the 10 patients were exquisitely sensitive to angiotensin II.
00:11:38
Speaker
So, Sergio, let's imagine a very inappropriate experiment where I take one of your young trainees and I give them 10 grams of enalopril, thereby shutting down all their angiotensin tube production.
00:11:51
Speaker
So, in order for me to give them the replacement dose of angiotensin that would be in their body, they would require five nanograms per kilo per minute.
00:12:02
Speaker
And what we found is that these two patients that were both north of 20 of norepi
00:12:09
Speaker
once they were on angiotensin II, they required less than the physiologic replacement dose, 2.5 nanogastrokiloprimenib, and all their other vasopressors came off, and they were hypertensive.
00:12:23
Speaker
And I did not have a provision for this in my protocol.
00:12:27
Speaker
I don't know who would have anticipated this, to be fair.
00:12:31
Speaker
and I had to stop the infusion early and report it as an adverse event.
00:12:36
Speaker
And then when I took the replacement dose of angiotensin 2 away, their background vasopressor just came back immediately.
00:12:45
Speaker
And so it wasn't just that the patients were getting better.
00:12:47
Speaker
And so one of the key findings of a very modest size pilot trial was that there was a group of patients in whom
00:12:57
Speaker
physiologic dose replacement angiotensin II completely altered their hemodynamic profile in a very positive way.
00:13:06
Speaker
And if you read that pilot trial that was published in Critical Care Medicine in 2014, you'll note that 20% of the patients receiving angiotensin II have the adverse event of hypertension in a shock trial, which I would argue is pretty uncommon.
00:13:21
Speaker
And so, you
Importance of Angiotensin Ratios
00:13:22
Speaker
know, yeah, go ahead.
00:13:22
Speaker
I'm sorry, I was going to, and maybe we don't know this yet, but do you know, was there something particular about their angiotensin 1 to angiotensin 2 profile or something in particular that you found that would predict that?
00:13:36
Speaker
Yeah, so this is a great question.
00:13:37
Speaker
And so at the time, it was my suspicion that they had been receiving ACE inhibitors and got sick.
00:13:45
Speaker
So one patient was a diabetic.
00:13:47
Speaker
The other one had a class two heart and was a heart failure patient.
00:13:51
Speaker
And I said, you know, the likely scenario here is that these folks had been suppressed, not unlike the way we treat an Addisonian patient who's been taking steroids or some other disease.
00:14:02
Speaker
And, you know, we wrote that up in the paper and that's basically what we put down.
00:14:07
Speaker
And if you look at ACE inhibitors,
00:14:09
Speaker
The half-life of these drugs are quite long.
00:14:12
Speaker
And so it was very rational to us that this was the case.
00:14:15
Speaker
And the reviewer at critical care responded back.
00:14:20
Speaker
And it turns out that the reviewer who gave me all this trouble was actually a dear friend of mine, Louis Forney.
00:14:24
Speaker
And he was a good friend then, but fortunately he was anonymous because he really criticized the heck out of us.
00:14:30
Speaker
And he said, you know, okay, this is a reasonable hypothesis, but were they, or were they not receiving angiotensin?
00:14:36
Speaker
And, um, um,
00:14:38
Speaker
inhibitors, ACE inhibitors.
00:14:40
Speaker
And so, you know, I sent my fellow to go back and, you know, pull the charts and we really couldn't find it in the MAR, in the medical reconciliation.
00:14:49
Speaker
So I wrote back to the journal and said, look, you know, this is America, you know, our healthcare system is not as, you know, robust with medical records as Europe.
00:14:58
Speaker
This is a reasonable hypothesis.
00:15:00
Speaker
And then they wrote back quite sharply, were they or were they not receiving ACE inhibitors?
00:15:07
Speaker
So then I took my fellow, I asked them to get a group of medical students together, and I informed them that they needed to go to the Walgreens, the CVSs, and all the pharmacies in the area, find all the outpatient doctors.
00:15:19
Speaker
And I said, this is a great hypothesis.
00:15:22
Speaker
You guys need to find the ACE inhibitor exposure.
00:15:23
Speaker
I'm sure it's there.
00:15:25
Speaker
So I sent them off on their mission, and they came back two or three weeks later, and they said, Mink, we can't find it.
00:15:31
Speaker
So, you know, we wrote this very sort of peculiar article
00:15:36
Speaker
you know, sentence in the discussion saying, we think it's ACE inhibitors, but we're not sure.
00:15:43
Speaker
And it was actually very good that this happened because we didn't understand this.
00:15:48
Speaker
And I started reading a lot more about angiotensin I, angiotensin II, and ACE.
00:15:55
Speaker
And as a nephrologist, I thought I knew this system pretty well.
00:15:58
Speaker
But one of the things that
00:16:01
Speaker
I knew, but I had forgotten is that angiotensin converting enzyme is not primarily a plasma enzyme.
00:16:08
Speaker
That enzyme lives on your endothelium, mostly in your pulmonary and your renal endothelium, but mostly in your pulmonary endothelium.
00:16:16
Speaker
And I thought to myself, well, maybe if you get severe endothelial injury in your lung, that would be a reason why you wouldn't be able to convert ang1 to ang2, and you would have this relative angiotensin 2 insufficiency.
00:16:31
Speaker
And then, you know, like I said, this whole process of angiotensin II, usually you're doing new experiments and new trials on learning.
00:16:38
Speaker
You know, I've had quite the opposite experience.
00:16:40
Speaker
I've joked with my friends and colleagues.
00:16:42
Speaker
I feel like this way is the lost art going into tombs and reading runes and old German texts.
00:16:48
Speaker
And we found a paper that was published in Circulation in 2000, wherein it's beautifully demonstrated that patients with ARDS
00:16:58
Speaker
their ability to convert angiotensin 1 to angiotensin 2 is linearly compromised by the severity of ARDS.
00:17:06
Speaker
Now, currently, in these days, we use the Berlin criteria, but back then they used a thing called the Murray Lung Injury Score.
00:17:13
Speaker
And what you find is the more severe your Murray Lung Injury Score, the more unable you are to convert ANG1 to ANG2.
00:17:21
Speaker
And when we went back to our pilot trial, both patients who had the exquisite
00:17:27
Speaker
sensitivity to angiotensin who both had severe ARDS.
Design of ATHOS III Trial
00:17:31
Speaker
One was on nitric oxide and the other was just about to get flip prone.
00:17:36
Speaker
So we then wrote an editorial to Critical Care outlining our hypothesis that
00:17:44
Speaker
patients who have severe endothelial injury, particularly those with likely ARDS, are likely the ones who have this angiotensin II insufficiency.
00:17:55
Speaker
And we also wrote in that paper that we thought that the angiotensin I to angiotensin II ratio would be a very thoughtful way to assess this because you can't measure endothelial function very effectively at the bedside.
00:18:07
Speaker
So we pre-specified in the APTHOS trial
00:18:12
Speaker
an assessment of the angiotensin 1 to angiotensin 2 ratio as a measure of ACE activity.
00:18:18
Speaker
And that was one of the key things that we did in the larger phase three trial.
00:18:24
Speaker
This is all super interesting and I think like you said, mentioned earlier, Mink, not something that we can just read upon in a review article, so I think it's fascinating.
00:18:34
Speaker
So I think that it's a good point.
00:18:35
Speaker
I mean, now to jump into Aethos III, you just mentioned, I mean, that now you, as you designed this second or the larger trial, you were already looking at these levels.
00:18:45
Speaker
You want to tell us a little bit about this trial?
00:18:48
Speaker
Sure, and so one of the things I want to tell people about in the Aethos III trial is
00:18:52
Speaker
is the rationale for why the study was designed the way that it was.
00:18:56
Speaker
So everyone, not everyone, I should say, let me be a little more thoughtful.
00:19:01
Speaker
Many people have complained and said, oh, well, all you demonstrated is that the blood pressure goes from 65 to 75.
00:19:06
Speaker
75 is not a blood pressure right target.
00:19:10
Speaker
The study is meaningless to me.
00:19:12
Speaker
Everyone knows angiotensin 2 makes the blood pressure go up.
00:19:15
Speaker
And I think that
00:19:16
Speaker
A reading of the abstract of the trial may allow for that type of opinion, but I think if people read the full paper and importantly read the supplement, the New England Journal asked us to write a pressee on the rationale for study design.
00:19:33
Speaker
And the rationale for study design was predicated on two important facts.
00:19:38
Speaker
Fact number one is that there has not been a single randomized controlled trial of any vasopressor that demonstrates a mortality benefit in shock.
00:19:48
Speaker
So while we all agree, and I would point out that I agree, and in my clinical practice I still see patients, norepinephrine is first-line therapy.
00:19:57
Speaker
And I agree that it should be first-line therapy.
00:19:59
Speaker
But that indication of first-line therapy is not based on a survival benefit.
00:20:05
Speaker
Everyone is familiar with the VAS data and the VANISH data, neither of which have shown an improvement in mortality slash survival with the use of vasopressin.
00:20:15
Speaker
In my clinical practice, I use vasopressin somewhere between 10 and 15 mics per minute of norepathy.
00:20:21
Speaker
That's my practice.
00:20:23
Speaker
And I use these drugs on a routine basis.
00:20:26
Speaker
I think most of us do.
00:20:27
Speaker
I think it's important to recognize that no vasopressor, none, has ever shown a mortality benefit.
00:20:33
Speaker
So when we went to FDA,
00:20:35
Speaker
they were acutely aware of this.
00:20:37
Speaker
And we said to them, we are not proposing a shock drug in the sense of this actually treats sepsis.
00:20:46
Speaker
So if you think about septic shock in particular, and I like to break this down into three large bins, when I care for a septic shock patient, I think about three things.
00:20:55
Speaker
One is hemodynamic support.
00:20:57
Speaker
Number two is source control.
00:21:00
Speaker
And number three is host response modulation.
00:21:04
Speaker
And so in the bin that is human dynamics, we all believe that maintaining inappropriate blood pressure is important.
00:21:12
Speaker
And the FDA agreed, and they agreed that the fact that there's only two classes of vasopressor available to treat a very severe syndrome would benefit from a third class of vasopressor.
00:21:26
Speaker
And that was the basis of designing a phase three registration trial.
00:21:32
Speaker
And at that meeting, when we agreed that MAP was the appropriate endpoint for a vasopressor, the question was, how can you demonstrate to us that this
Trial Endpoints and Efficacy
00:21:42
Speaker
is a vasopressor?
00:21:42
Speaker
And so my initial proposal was to show catecholamine reduction.
00:21:48
Speaker
And I initially proposed a 50% reduction in catecholamine as being an appropriate endpoint.
00:21:55
Speaker
And the FDA said,
00:21:57
Speaker
you're telling us the drug is a vasopressor, correct?
00:22:01
Speaker
We said, yes.
00:22:02
Speaker
And they said, then you must demonstrate that the blood pressure goes up.
00:22:06
Speaker
Catecholamine sparing can be done with other agents through other mechanisms.
00:22:11
Speaker
That's not blood pressure going up.
00:22:13
Speaker
That could mean something that's related to blood pressure.
00:22:16
Speaker
We understand why you would arrive at that as a reasonable hypothesis.
00:22:20
Speaker
You must demonstrate to us that the blood pressure goes up.
00:22:24
Speaker
So we said, okay, what would you like?
00:22:27
Speaker
And they said, demonstrate to us a meaningful increase in blood pressure.
00:22:32
Speaker
And that's how we arrived at raising the blood pressure from 65 to 75 or a delta 10.
00:22:39
Speaker
But we informed the FDA that it is not standard practice in all ICUs to raise people's blood pressure to 75 for an extended duration of time.
00:22:49
Speaker
and that even though the sepsis spam as far data demonstrated no harm, most physicians will not maintain a map of 75 to 80 in their shock patients.
00:23:00
Speaker
Some might, but this is not standard practice.
00:23:03
Speaker
So we arrived at this three hour trial where angiotensin II versus placebo is titrated in order to demonstrate the blood pressure goes up for three hours with the standard of care vasopressors staying still.
00:23:20
Speaker
Therefore, ensuring that the only thing that could be causing the blood pressure to go up is the angiotensin II.
00:23:25
Speaker
And then from three hours to 48 hours, the clinicians could titrate the angiotensin II as they saw fit, thereby demonstrating catecholamine sparing, which is why our secondary endpoint was cardiovascular sulfoscore.
00:23:40
Speaker
Now, we actually asked them to actually look at norepinephrine dose, but they said they wanted a consensus guideline as a secondary endpoint, hence cardiovascular score.
Safety and Subgroup Analysis
00:23:50
Speaker
So the trial was essentially a demonstration of blood pressure increase as per our negotiation with FDA.
00:23:59
Speaker
and catecholamine reduction.
00:24:01
Speaker
And we demonstrated both of those in ATHOS-3.
00:24:05
Speaker
And so that was the rationale for the trial.
00:24:08
Speaker
Now, many people have also stated that what we should have done is a head-to-head trial instead.
00:24:14
Speaker
And the reason why we did not do that, and it's very important, the other large consideration for FDA, of course, is efficacy.
00:24:23
Speaker
But I think people underestimate and do not think about how much their
00:24:29
Speaker
responsibilities related to safety.
00:24:32
Speaker
So in order for FDA to approve a drug, they want to feel very confident that the drug is safe.
00:24:38
Speaker
And if you compare angiotensin II to vasopressin, as an example of a trial, what you would have is adverse events that occur on both sides.
00:24:49
Speaker
Well, it's very hard to ascertain what's an angiotensin II effect versus a vasopressin effect because they're both in the same drug class.
00:24:57
Speaker
They're both vasopressors.
00:24:59
Speaker
So they asked us to go against placebo.
00:25:02
Speaker
And the rationale, of course, when you do a placebo-controlled trial is if you see an imbalance in adverse events, you can feel much more confident that those adverse events are occurring due to the drug.
00:25:17
Speaker
Now, one of the things that was very striking, and I think one of the things that pleased me the most about the study, is that adding angiotensin II, a potent vasopressor, resulted in fewer numerical serious adverse events than those patients who were in the placebo arm.
00:25:37
Speaker
And in critical care, there's no free lunch.
00:25:39
Speaker
If you add dobutamine, you're not surprised when you get tachycardia and hypotension.
00:25:44
Speaker
If you add milrinone, not surprising for the same.
00:25:47
Speaker
We are used to paying the cost of adding a therapy.
00:25:51
Speaker
And it's not that I think that angiotensin 2 doesn't have toxicity.
00:25:55
Speaker
I'm confident that it does.
00:25:57
Speaker
But because you're able to use angiotensin 2 and decrease the dose of toxic catecholamines, you get the offset wherein you get a similar safety profile.
00:26:08
Speaker
And so I think in aggregate, the way people should view ethos 3 is not that it was trying to be vast.
00:26:16
Speaker
It wasn't.
00:26:17
Speaker
This was a very complex
00:26:20
Speaker
well-designed trial that was set out to do one and only one thing, which is to demonstrate safety, which we did, and efficacy as a vasopressor.
00:26:32
Speaker
And that's what it was set up to do.
00:26:34
Speaker
Yeah.
00:26:34
Speaker
And I think that's a very important point that I've also, I mean, discussed with many people and 100% agree, understanding what we're trying, what we're asking from our trials.
00:26:44
Speaker
I mean, every trial can't answer every question, right?
00:26:46
Speaker
And I think that this, from my point of view, opens the door.
00:26:52
Speaker
It's not a definitive study, like you said, but it opens the door.
00:26:55
Speaker
And I think that now we have additional data that's coming up.
00:27:00
Speaker
And I don't know if you want to jump now and maybe tell us a little bit, Mink, about the recently published data in critical care medicine regarding the outcomes in those patients who had vasodilatory shock and were also initiated on renal replacement therapy.
00:27:15
Speaker
Yeah, thanks very much, Sergio.
00:27:17
Speaker
I want to just talk about
00:27:20
Speaker
subset data before we talk about this particular subset and my view of subset data.
00:27:27
Speaker
So many people feel that subset data, even if it was pre-specified or post-hoc, is meaningless.
00:27:34
Speaker
And I couldn't disagree more.
00:27:36
Speaker
I think one of the things that people need to recognize is that when you do a registration trial,
00:27:42
Speaker
for the FDA and for a regulator, they insist that you pre-specify important subgroups.
00:27:49
Speaker
And the reason is not just to maybe find hypothesis generating groups that may enjoy benefit, but the most important thing is to identify subsets from which they might be harmed.
00:28:01
Speaker
That's why these subsets are pre-specified.
00:28:04
Speaker
So we identified multiple subsets, and I'll tell you about the results of those findings, but the way, in my view,
00:28:12
Speaker
you should look at the subset data is to inform you of whether there is a harm signal.
00:28:18
Speaker
We know that for broad classes of drugs that there's certain groups of patients you should avoid.
00:28:25
Speaker
And you avoid them because if they get that drug, bad things happen.
00:28:28
Speaker
Similarly, you can imagine a group of patients where an angiotensin 2 isn't good for them.
00:28:34
Speaker
So the first subset that we looked at, and these data were basically
00:28:41
Speaker
were presented in abstract form were the group of patients with high severity of illness.
00:28:46
Speaker
So we want to know as intensivists, does a high Apache 2 score identify a group of patients who does better, does worse, or does about the same?
00:28:56
Speaker
And what we showed is that for those patients, and this is a pre-specified analysis with an Apache 2 score greater than 30, they enjoyed a survival benefit.
00:29:05
Speaker
And that's what you would expect.
00:29:07
Speaker
And that survival benefit was statistically significant with a p-value of 0.04.
00:29:12
Speaker
And so more severely ill, they're outrunning you.
00:29:16
Speaker
Does a rescue vasopressor help you?
00:29:18
Speaker
The answer is yes.
00:29:19
Speaker
And importantly, in the patients with an Apache score less than 30, it's not zero sum.
00:29:26
Speaker
We just show no benefit, but we do not show harm.
00:29:29
Speaker
Similarly, we looked at patients who had a mean arterial pressure less than 65 at baseline.
Benefits for Renal Therapy Patients
00:29:37
Speaker
Now, of course, we all know that in surviving sepsis, the European guidelines, and in every single shock guideline, the baseline map that you should achieve is 65.
00:29:52
Speaker
And when FDA asked us to pre-specify this group of patients, I said, look, guys, this is an RCT.
00:29:59
Speaker
These investigators are not going to put in patients who are on high-dose norepinephrine vasopressin who are not achieving a MAP less than 65.
00:30:07
Speaker
I said that in my clinical practice, I very rarely let people be less than 65, and I will use more catecholamine and vasopressin to do it.
00:30:16
Speaker
And FDA said, you know, Mink, that's great.
00:30:19
Speaker
We really think you have a nice opinion.
00:30:21
Speaker
Do it anyway.
00:30:23
Speaker
And I was, of the many things I've been humbled on in this trial, and this is one of them, fully one third of the patients in the trial had a baseline MAP less than 65.
00:30:35
Speaker
One third.
00:30:37
Speaker
I was stunned.
00:30:40
Speaker
Because this is a randomized control trial that occurred in some of the best centers around the world.
00:30:46
Speaker
United States, Canada, Australia, New Zealand, you know, the UK, Germany.
00:30:52
Speaker
Brussels and Belgium and France and Finland.
00:30:56
Speaker
And these are all the top centers.
00:30:58
Speaker
One third of the patients have a baseline map less than 65.
00:31:01
Speaker
And what we demonstrate is that those patients have a much better response and blood pressure.
00:31:08
Speaker
You can now get them above 65 because many of these folks are generally viewed as moribund.
00:31:14
Speaker
You didn't think anything could happen.
00:31:15
Speaker
And we actually showed a very nice survival trend improvement.
00:31:18
Speaker
And these data have also been published in abstract form.
00:31:21
Speaker
But importantly, we also looked at this group of patients who mechanistically were linked to angiotensin II.
00:31:29
Speaker
This is the group of patients who have an angiotensin I and angiotensin II ratio that's high.
00:31:35
Speaker
So just by way of background, if you take the CIRA of healthy volunteers or look at the angiotensin I and angiotensin II ratio in otherwise healthy hypertensive patients, what you find is a normal ratio is around 0.5.
00:31:50
Speaker
which means that you have around two times as much angiotensin II as angiotensin I normally.
00:31:56
Speaker
In the trial, we demonstrate that the median value, this is a pre-specified analysis, of angiotensin I to angiotensin II ratio is 1.6, which means that in shock, your ACE function is highly disordered.
00:32:10
Speaker
And this is almost certainly due to endothelial dysfunction.
00:32:13
Speaker
This alone, I think, is a very important finding that people are not really focusing on.
00:32:19
Speaker
in shock your ace function is defective in the subset whose median ang1 ang2 ratio is above 1.6 they enjoy a highly statistically significant survival benefit and then those patients with a ratio less than 1.6 there's no difference but there's no harm and the most recent data that you alluded to that we were really excited about is we looked at patients who were
00:32:47
Speaker
had acute kidney injury, and who were on dialysis at baseline.
00:32:51
Speaker
So you're in the trial, you're on a lot of vasopressor, you're already on some form of renal replacement therapy.
00:32:59
Speaker
Now, in this patient population, they have an even more disordered ACE defect because their median value of ANG1-ANG2 ratio is north of two.
00:33:10
Speaker
I believe it was around 2.3 or 2.4.
00:33:13
Speaker
So this is some of the most disordered patients in the trial.
00:33:17
Speaker
They have the most defective ANG1-ANG2 ratios, meaning that they're angiotensin II relatively insufficient.
00:33:24
Speaker
And in the group on dialysis that's hit, it receives angiotensin II exogenously,
00:33:30
Speaker
They enjoy a substantial mortality benefit to the tune of a P. value of 0.01.
00:33:35
Speaker
This holds up in a multivariate analysis, but most importantly, quite strikingly, they recover from dialysis more rapidly than placebo.
00:33:45
Speaker
Half the patients who received angiotensin 2 are off renal replacement therapy at 7 days versus 20% in the other arm.
00:33:53
Speaker
And as a nephrologist who spent a lot of time in the AKI world, I did not think it was possible to help people once they were on dialysis.
00:34:02
Speaker
I've been teaching for about 20 years that once they're on dialysis, it's too late.
00:34:07
Speaker
You miss the boat.
00:34:08
Speaker
You fail to resuscitate them.
00:34:09
Speaker
You fail to do all the things you need to do to get them better.
00:34:12
Speaker
And I was really quite humbled with this result.
00:34:14
Speaker
And, you know, people have been
00:34:18
Speaker
sort of giving us a hard time saying, just increasing blood pressure doesn't really
Angiotensin-2 as a Unique Vasopressor
00:34:24
Speaker
do anything for you.
00:34:24
Speaker
There's no cost savings.
00:34:26
Speaker
Well, I'm here to tell you that as an AKI expert, that coming off of dialysis is a good thing, and not being a CKD patient is a good thing, and not being an ESRD patient in the future is a good thing.
00:34:39
Speaker
And not surprisingly, those patients who come off of dialysis faster have less ventilator days and spend less time in ICU.
00:34:44
Speaker
So
00:34:45
Speaker
We will hope to go on and further validate this because it was a subset, it was a post hoc analysis, so we are obliged to do another study and show that in the future.
00:34:56
Speaker
But these findings are mechanistically linked because we know those patients who are angiotensin II deficient cannot maintain efferent tone, they cannot maintain GFR, and we pre-specified that we thought this ang1-ang2 ratio might be important.
00:35:13
Speaker
And so in aggregate, I think that if you look at all the subset data, I think that our conclusion, and I think people should feel free to challenge this and give another view of it, is that angiotensin II is not just another vasopressor, in my view.
00:35:31
Speaker
It's, in many patients, the missing vasopressor.
00:35:35
Speaker
Not another vasopressor, it's a missing vasopressor.
00:35:38
Speaker
And the subset data, yeah, go ahead.
00:35:40
Speaker
So go ahead, go ahead.
00:35:42
Speaker
Sorry, go ahead.
00:35:43
Speaker
No, I was just going to say that.
00:35:44
Speaker
And then as a clinician, we know that it will help you raise blood pressure.
00:35:49
Speaker
It'll help you unload your catecholamines.
00:35:53
Speaker
There are important subsets where they enjoy a survival benefit.
00:35:57
Speaker
But most importantly, there is no subset for which we have found that angiotensin 2 creates harm.
00:36:04
Speaker
And that to me is the most important thing.
00:36:06
Speaker
Of all the things that exist, yes, we always wanna go for mortality benefit.
Safety Profile of Angiotensin-2
00:36:10
Speaker
Yes, we want fewer ventilator free days.
00:36:11
Speaker
Yes, we want to come off with dialysis good.
00:36:13
Speaker
Those are all good things.
00:36:15
Speaker
But for me to bring a drug to market and have a drug that is now available that we cannot demonstrate harm, that to me is a really important takeaway finding because that's what the clinician at the bedside needs to have comfort with.
00:36:30
Speaker
Yeah, and I think that historically, for some of our younger viewers, there have been compounds that have been studied in sepsis that did raise blood pressure, but also increased mortality.
00:36:41
Speaker
So this is not something that just we should assume that, oh, anything that raises blood pressure in a shock state is probably not going to be harmful because there have been drugs that actually have been harmful prior to
00:36:52
Speaker
for other mechanistic reasons.
00:36:54
Speaker
So that's, I think, like you said, make a very important point.
00:36:58
Speaker
One question I do have, and it's one of the clarification for the audience, is in the subset of patients that you looked at with the benefit, with the renal replacement therapy, that excluded patients who were ESRD prior to getting sick, correct?
00:37:14
Speaker
Yes, that's right, and that's an important point to make.
00:37:16
Speaker
Yes, the ESRD patients were excluded from that analysis because obviously they didn't have the opportunity to get better.
00:37:23
Speaker
But it was a very small number of patients in the trial who had ESRD.
00:37:27
Speaker
Excellent.
00:37:28
Speaker
So I think that, as you were discussing, Mink, there's a lot of very interesting aspects about agitensin II.
00:37:35
Speaker
Like you mentioned, it's a different pathway.
00:37:38
Speaker
So it could be viewed, I mean, from a physiological standpoint for the right patients as a
00:37:43
Speaker
complementary approach that might be very targeted in some subsets.
00:37:47
Speaker
But I guess in terms of real life and practicality, now it's approved, it's commercially available.
00:37:54
Speaker
In your view today, how would you insert Jepressa or Aditansin II into the treatment, into the paradigm treatment of shock?
Multimodal Approach in Shock Treatment
00:38:02
Speaker
Yeah, thank you, Serge.
00:38:03
Speaker
I think that's a really important question.
00:38:04
Speaker
So let me just sort of share with you a bias that I have.
00:38:08
Speaker
And I don't think everyone agrees with this, but let me share it with you because I think it's important for the recommendation that I'll give based on the data.
00:38:16
Speaker
Generally speaking, it's my view that single bullet, silver bullet therapies are no longer the key to gaining significant traction in difficult to treat diseases.
00:38:30
Speaker
So if you sort of look at HIV, we had many, many drugs that were available that could decrease viral load.
00:38:36
Speaker
It wasn't until we had multi-mode therapy that we got traction.
00:38:40
Speaker
The same is true for hepatitis C.
00:38:42
Speaker
And then people say to me, well, Mink, those are infectious diseases, it's different.
00:38:45
Speaker
And I say, okay, well, if you look at something like oncology, even people who have, who respond to Gleevec, don't get Gleevec alone.
00:38:54
Speaker
You need more than one drug.
00:38:55
Speaker
No one just gets cyclophosphamide.
00:38:58
Speaker
And people say, yeah, fair enough, but that's cancer.
00:39:01
Speaker
So I would point out an inflammatory disease.
00:39:05
Speaker
So we think that vasodilatory shock is largely inflammatory disease.
00:39:10
Speaker
There isn't a patient I know who's just getting better on Humira for rheumatoid arthritis.
00:39:15
Speaker
They're not just getting better on steroids alone.
00:39:17
Speaker
They're not just getting better on methotrexate alone.
00:39:18
Speaker
What we find is a combination of therapies used in lower doses, decreases toxicity, and you get synergy.
00:39:27
Speaker
And I think the best example of this is in hypertension.
00:39:31
Speaker
All of us treat hypertensives.
00:39:33
Speaker
There's nobody who is out there who has a patient on nine grams of metoprolol.
00:39:40
Speaker
That's not what we do.
00:39:43
Speaker
And then you don't see someone on 9 grams of metoprolol, even if they existed, then get added on to labetalol.
00:39:50
Speaker
We don't see patients walking around who are on labetalol and metoprolol.
00:39:54
Speaker
But in the ICU, it's very common for someone to say, well, they're on norepi, they're failing, let me add epi.
00:40:00
Speaker
This to me is deeply illogical.
00:40:02
Speaker
I don't understand it.
00:40:04
Speaker
I don't understand how epi is going to save you and nor epi is not saving you because there's some beta receptor out there that you haven't found.
00:40:12
Speaker
This doesn't make any sense to me.
00:40:14
Speaker
We don't do this in any other disease.
00:40:16
Speaker
And so it's my very strong view that multimode therapy is rational.
00:40:22
Speaker
And what we saw in the clinical trial is that patients were
00:40:28
Speaker
99% of patients in ATHOS3 were on norepinephrine, and another 70% were on vasopressin.
00:40:34
Speaker
And we added angiotensin II to them.
00:40:37
Speaker
And I think this is very logical.
00:40:39
Speaker
If you think about neurohormonally, how we all take care of ourselves, we used a balanced approach.
00:40:47
Speaker
I mean, take, for example, Sergio, imagine one morning you come in, you're on service, you haven't had your coffee,
00:40:53
Speaker
You haven't had a glass of water all day.
00:40:55
Speaker
It's now three o'clock in the afternoon.
00:40:56
Speaker
You haven't had a thing to eat or drink.
00:40:59
Speaker
You're not hypotensive.
00:41:01
Speaker
And neurohormonally, you've defended your blood pressure through heart rate and cardiac output.
00:41:06
Speaker
And it is almost certain that you have
00:41:09
Speaker
increase the production of catecholamines, vasopressin, and angiotensin to defend your blood pressure.
00:41:15
Speaker
And to me, this is what I think we should be doing clinically.
00:41:18
Speaker
If people are failing current drugs, then it makes sense to me to use multimode therapy.
00:41:25
Speaker
And I think that's the approach that we did in our clinical trial, and that's what I would like to see people do clinically.
00:41:33
Speaker
To me, this is a highly logical way of moving forward.
00:41:38
Speaker
So in terms of just some practical points, a lot of listeners, I'm sure, have not had the opportunity to utilize the drug.
Dosing and Strategies for Use
00:41:46
Speaker
I know that the recommended dosing is in nanograms per kilogram per minute and that it's recommended that you start at a dose of 20 nanograms and increase by 15.
00:41:57
Speaker
And then the range really seems to be for utilization between 2.5 and 40 nanograms per kilogram per minute.
00:42:06
Speaker
Is that correct?
00:42:08
Speaker
That's right.
00:42:10
Speaker
And what about... So let me tell you what... Go ahead.
00:42:12
Speaker
Yeah, go ahead.
00:42:12
Speaker
No, no, go ahead.
00:42:14
Speaker
What we saw in the clinical trial and the use that we typically saw is that when patients got started on angiotensin II,
00:42:22
Speaker
if they had a brisk response, what we typically saw people do is come off of the high-dose epi first for a lot of obvious reasons.
00:42:30
Speaker
Typically, when you're on high-dose vasopressors and you're on epi, typically you see a lot of the side effects of epi.
00:42:38
Speaker
So what we saw in the clinical trial is when there was a blood pressure response is moving the catecholamines rapidly out of their toxic range.
00:42:47
Speaker
And then once the catecholamines are down below a toxic range, and in my view, that's sort of getting your epi off and your norepi down to around 20 mics per minute or 0.2.
00:42:57
Speaker
And that's what we saw in the clinical trial people would do.
00:43:01
Speaker
And then what we saw is that depending on
00:43:04
Speaker
people's views of which vasopressor they like more or not, meaning vasopressin.
00:43:11
Speaker
The vasopressin would come off quickly or some people will leave it on longer and then take all three down together.
00:43:15
Speaker
I think all those approaches are reasonable.
00:43:18
Speaker
I think that, of course, the bedside clinician, once they get
00:43:22
Speaker
down to lower doses of each, which is what we saw in the clinical trial, they'll use their bedside acumen to determine what they need more or less of.
00:43:32
Speaker
And I think a lot of it will determine if they're having tachyarrhythmias or not, or if they're having any side effects due to things which are catecholamine related.
00:43:39
Speaker
And so what we saw in the trial is adding angiotensin to, and then when there was a response, being able to move down off of the others in pretty short order.
00:43:53
Speaker
And I think that in terms of how I'm thinking about this drug based on what we discussed and what I've read, you were very clear, Mink, that this is not your go-to drug for everybody with distributive shock.
Integration into Clinical Practice
00:44:05
Speaker
It's a part of a multimodal approach, especially when people start failing our first-line therapy, such as norepinephrine.
00:44:11
Speaker
There might be some subsets of patients who hopefully will get more data that might benefit even further.
00:44:18
Speaker
But right now in 2018, as we introduce this to our clinical practices, obviously a lot of the discussion is around value.
00:44:26
Speaker
And I look at value as patient outcomes over cost.
00:44:30
Speaker
So things that improve patient outcomes or things that decrease cost or hopefully both are things that I think are easier to introduce and support with value.
00:44:40
Speaker
What would be your value proposition in 2018 for this new drug?
00:44:47
Speaker
Yeah, I think that's a really important question.
00:44:48
Speaker
And given where we are in health care,
00:44:51
Speaker
and that we've all become appropriately cost sensitive.
00:44:55
Speaker
This is the question.
00:44:56
Speaker
And so I'll tell you what different groups are doing now.
00:45:01
Speaker
And most people are using angiotensin II on label, which means that it's norepinephrine, vasopressin, they add angiotensin II.
00:45:10
Speaker
And if you look at the label, and it's not so easy to find, but what you'll find is that if you want to get value from angiotensin II, you really need to use it before they're on 50 of norepia or 0.5.
00:45:22
Speaker
What you see in the label is patients who start angiotensin II before you're on very high-dose vasopressors get a much more robust blood pressure response.
00:45:31
Speaker
And we know that when you get a more robust blood pressure response, everything else gets better more rapidly.
00:45:35
Speaker
And that's in the label, although it's not really clearly identified.
00:45:39
Speaker
And I think that the approach that we saw in the clinical trial was exactly this, norepinephrine, vasopressin, and then before going back to another catecholamine, going to angiotensin II.
00:45:51
Speaker
And when that happens, what we find is this nice trend line towards survival benefit, which is also in the label.
00:45:58
Speaker
But more importantly, in these important subsets that we have published, you also enjoy a survival benefit.
Cost and Value Proposition
00:46:06
Speaker
I will say, though, that what we've also seen is that
00:46:10
Speaker
The average number of days in the clinical trial for which people need angiotensin 2 is around two days.
00:46:18
Speaker
And, you know, let's be very direct about this surgery.
00:46:20
Speaker
Let's not beat around the bush because I think people want to know what the price is and they want to know how much things cost.
00:46:26
Speaker
So angiotensin 2 per vial and for 90 plus percent of your patients, they need one vial per day.
00:46:34
Speaker
is $1,500 a vial.
00:46:36
Speaker
And a lot of people sort of say, well, that's a lot of money.
00:46:40
Speaker
And there's no getting around the fact that it's certainly not as cheap as norepinephrine.
00:46:45
Speaker
It is what it is.
00:46:47
Speaker
And if you look at the cost of vasopressin, so there's usually three vials of vasopressin in a bag.
00:46:53
Speaker
And so generally speaking, angiotensin II is twice the cost of vasopressin, although different markets, different hospitals, this may vary.
00:47:01
Speaker
And I think a lot of people
00:47:03
Speaker
still say, hey, that's very expensive, although I think other people were expecting Zygris pricing, to be fair.
00:47:08
Speaker
And for those of you who don't know what Zygris was, it was a drug that came with enormous sticker shock.
00:47:15
Speaker
But as a company, I will say that it being 20 years after Zygris and being, you know, half its cost was something that as a company we were very proud of because we wanted to get this drug to patients because we think that matters.
00:47:28
Speaker
And what we have seen some centers do, and by no means am I saying this is what people ought to do, but because most patients are on vasopressin for three to four days, we've seen clinical pharmacologists do the math and say, well, essentially, these are the same.
00:47:46
Speaker
And I think that's something that every center will have to sort out for themselves to make a decision on what the value proposition is.
00:47:52
Speaker
The SACHA data that was just published in the Cleveland Clinic shows that around 40% of patients who receive vasopressin get a blood pressure response.
Combination with Vasopressin
00:48:03
Speaker
In ATHOS-3, the number was 70% and 80% at one hour.
00:48:08
Speaker
So I think that people are getting into this habit of pitting in their brain angiotensin II versus vasopressin.
00:48:16
Speaker
And because there's costs associated with both of them,
00:48:20
Speaker
they're swapping them.
00:48:22
Speaker
But I'll be honest with you, it's my view that multimode therapy makes sense.
00:48:26
Speaker
So in 70 years, whenever it is, or 10 years or five years, or who knows when these things work out because vasopressin now is a branded generic and I don't know how long their IP is, but at some point when all these drugs in the far future are generic, I think people will put them together much earlier, much more rapidly because it's highly logical.
00:48:47
Speaker
I think in an environment,
00:48:49
Speaker
where costs are there, I think people have to think more thoughtfully about it, and that makes sense to me.
Effective Use and Early Intervention
00:48:55
Speaker
So what I would say is that the value proposition, in my view, is exactly as it was used in the ATHOS-3 trial, which is to use it in the third-line position, but not when the patient is dead already.
00:49:08
Speaker
And I think people know what I'm talking about who are intensivists.
00:49:10
Speaker
If you're going to use it, use it early third-line like it was used in the trial if you want to see a similar kind of benefit.
00:49:19
Speaker
And I think that that makes a lot of sense.
00:49:21
Speaker
And I think that, like you said, in terms of adding vasopressors, which is no different from no vasopressor to your first vasopressor, time does matter.
00:49:31
Speaker
And I think that we need to do that in a timely, it's a time-sensitive intervention.
00:49:36
Speaker
And the same thing in terms of adding a second vasopressor or a third vasopressor.
00:49:39
Speaker
We configure those things pretty quickly.
00:49:41
Speaker
And I think that I agree, Mink.
00:49:43
Speaker
We should be very, very sensitive of that timing.
00:49:47
Speaker
Well, this has been a fascinating conversation.
00:49:50
Speaker
I think that we could keep going for a long time.
00:49:53
Speaker
But I do want to thank you for...
00:49:56
Speaker
Sharing with us all this information about Angitensin II, I'm sure that all the listeners will be very interested in learning as new data comes.
00:50:05
Speaker
Keep learning about this drug, start utilizing it, and finding, like you said, the best profile of patients that really would gain the greatest benefit from this new treatment.
Personal Insights and Career Reflections
00:50:15
Speaker
One of the things that we usually do in critical matters is at the end, tap into the wisdom of our guest and talk about a couple of topics that are a little bit not medical, but still related to the practice of critical care.
00:50:27
Speaker
Would that be okay?
00:50:29
Speaker
I'd be delighted.
00:50:30
Speaker
So the first question, Mink, is what book or books have influenced you the most, or if you rather, what book have you gifted most often to others?
00:50:40
Speaker
So the book that changed my life was Atlas Shrugged.
00:50:43
Speaker
It was given to me by my best friend in my second year of medical school.
00:50:48
Speaker
And even though I don't necessarily subscribe to all the belief structure of Ayn Rand, which I don't,
00:50:54
Speaker
But that book absolutely changed my life.
00:50:56
Speaker
It changed the way I viewed many things and it was very inspirational.
00:51:01
Speaker
And I think I've gifted that book no less than 10 times in my life to people.
00:51:05
Speaker
And so it was actually a pivotal point in my life and my career.
00:51:11
Speaker
And it really had a huge impact on me.
00:51:14
Speaker
That's awesome.
00:51:15
Speaker
And we'll add all the studies that we mentioned and also the book in the show notes so our listeners can check them out.
00:51:22
Speaker
The second question is,
00:51:24
Speaker
is what do you believe to be true in medicine or in life that most other people don't believe?
00:51:31
Speaker
So this is gonna be very personal and it may offend some of your listeners.
00:51:35
Speaker
So for those of you who are listening, please don't take it too hard.
00:51:39
Speaker
But Serge, you know, I have a connection back to a town in South Jersey called Cherry Hill.
00:51:46
Speaker
And I believe the Eagles will repeat in the Super Bowl this year, this coming season.
00:51:51
Speaker
And I'm confident that very few people subscribe to this.
00:51:54
Speaker
I don't know if they subscribe to the possibility or do they wish that, but that's about two different things.
00:51:59
Speaker
But I think it counts both ways.
00:52:01
Speaker
Well, I will tell you, it is the first time in my lifetime, aside from the Eagles winning, that Cowboys fans, Redskins fans, and Giants fans were all rooting for the Eagles in the Super Bowl.
00:52:10
Speaker
And that will never happen again.
00:52:12
Speaker
Now everyone can feel free to hate us again.
00:52:14
Speaker
And I think that's probably largely deserved.
00:52:17
Speaker
True.
00:52:18
Speaker
I'll true that.
00:52:19
Speaker
And finally, what would you want every intensivist who's listening to this podcast to know?
00:52:26
Speaker
So I think that this is also very personal and it's something that I want people to understand that things were going very well for me in Washington, D.C.
00:52:36
Speaker
I had a very nice academic career.
00:52:38
Speaker
And the reason I took this abrupt left turn in my life to pursue energy attention to is because I thought it was very special and important.
00:52:47
Speaker
And I just want to share with people my thesis on why I think this is important.
00:52:52
Speaker
And it goes as follows.
00:52:54
Speaker
MAP matters.
00:52:55
Speaker
This is a huge bias that I have, but MAP matters and maintaining appropriate MAP matters to patients who are in shock.
00:53:04
Speaker
And by extension, if MAP matters for certain patients who are outrunning you, it requires the use of toxic doses of other vasopressors.
00:53:16
Speaker
And those toxicities are non-trivial and I think contribute to the high mortality that we see in shock patients.
00:53:26
Speaker
And it was this exquisite sensitivity of angiotensin II in this subset of patients that led me to make this abrupt left turn and try and work on angiotensin II because I thought it would be very important.
00:53:39
Speaker
I think that we owe the community more data.
00:53:42
Speaker
And we will endeavor to get that to the community as soon as possible.
00:53:47
Speaker
I think people should recall my bias, not just my potential financial conflict, but my scientific bias.
00:53:55
Speaker
But my my one message to all my fellow intensivists is when someone is out running you, Matt matters and this tools in the toolbox and it's going to help you.
00:54:07
Speaker
And I will tell you that.
00:54:09
Speaker
No one goes into critical care for the alcoholism or the high divorce rate for the late hours and missing all that important family time.
00:54:18
Speaker
We do it for the saves.
00:54:20
Speaker
And very few people get to talk about this.
00:54:23
Speaker
People who are in the military, police officers, firemen, nurses, surgeons, intensivists.
00:54:30
Speaker
It's a very small group of people who are in this acute care space.
00:54:35
Speaker
And we take on, you know, insanity in our lives and we see things that other people don't see.
Conclusion and Closing Remarks
00:54:42
Speaker
And we do it largely because we want to be able to take that person who's on a knife's edge and get them in the right direction.
00:54:51
Speaker
And so what I will say to my fellow intensivists out there, map matters.
00:54:57
Speaker
If you use angiotensin II in the thoughtful way that was in the label, you'll find that will help you.
00:55:03
Speaker
Excellent.
00:55:04
Speaker
I think that the concept of defending the map is where I think will stop.
00:55:09
Speaker
Mink, it was a great pleasure to have you on.
00:55:11
Speaker
I'm sure that we'll have a lot more conversations and hopefully we'll have you as a guest in the future.
00:55:17
Speaker
Thanks Sergio very much.
00:55:18
Speaker
I really appreciate it and congratulations on putting together a really outstanding series.
00:55:22
Speaker
This is one of the podcasts I listen to as well.
00:55:24
Speaker
So it's a real privilege for me to be someone who you've actually interviewed.
00:55:28
Speaker
Thank you.
00:55:32
Speaker
Thanks again for listening to Critical Matters.
00:55:35
Speaker
Make sure to subscribe to this podcast on iTunes or Google Play.